Tiwari S.Sharma B.Deka J.Singh P.Chatruvedi V.K.2025-01-132025-01-132024978-075036136-1; 978-075036132-3https://dl.bhu.ac.in/ir/handle/123456789/1396Chronic infection of liver cells causes scarring on liver tissue, resulting in LiverFibrosis (LF), which is now a major global health concern. Hepatitis C, Hepatitis B,and alcohol abuse are the leading causes of liver damage, which results in thedeposition of Extracellular cell matrix (ECM) and liver fibrosis. Ultrasonography andmagnetic resonance imaging are commonly used as non-invasive diagnostic methodsfor hepatic fibrosis. The conventional therapy used to treat liver diseases is ineffectivebecause it does not deliver a sufficient amount of drug concentration in the liver and isimprecise. Several clinical and preclinical Study has shown that the utilisation ofnanotechnology to deliver therapeutic agents including drug molecules, and nucleicacids, in adequate amount and to target specifically the HSC (hepatic stellate cells)could be the future treatment to cure Liver diseases caused by LF. According toresearch, nanomedicines can reverse premature hepatic fibrosis. Many nanoparticulate systems (NPs) such as Liposomes, Inorganic NPs, and Nano-micelles have beenstudied because of their diverse properties for drug delivery and in addition to sometherapeutic moieties. Out of these, Liposomal NPs have shown very promising resultsin clinical trials and are being considered as an extremity for the treatment of hepaticfibrosis. This book chapter discusses the causes, pathogenesis, diagnosis, and nanoparticulate systems used in the treatment of chronic liver diseases. � IOP Publishing Ltd 2024. All rights reserved.enBook chapter10.1088/978-0-7503-6134-7ch11